1
|
Piana S, Zanetti E, Bisagni A, Ciarrocchi A, Giordano D, Torricelli F, Rossi T, Ragazzi M. Expression of NOTCH1 in thyroid cancer is mostly restricted to papillary carcinoma. Endocr Connect 2019; 8:1089-1096. [PMID: 31265994 PMCID: PMC6652246 DOI: 10.1530/ec-19-0303] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/26/2019] [Accepted: 07/02/2019] [Indexed: 12/21/2022]
Abstract
The NOTCH signaling is an evolutionarily conserved signaling pathway that regulates cell-cell interactions. NOTCH family members play a fundamental role in a variety of processes during development in particular in cell fate decisions. As other crucial factors during embryogenesis, NOTCH signaling is aberrantly reactivated in cancer where it has been linked to context-dependent effects. In thyroid cancer, NOTCH1 expression has been associated to aggressive features even if its in vivo expression within the entire spectrum of thyroid tumors has not definitively established. A series of 106 thyroid specimens including non-neoplastic lesions, benign and malignant tumors of common and rare histotypes, were investigated by immunohistochemistry to assess NOTCH1 expression. Extent of positivity and protein localization were investigated and correlated with clinical and morphological parameters. NOTCH1 positivity was predominantly associated with papillary carcinomas and only occasionally found in follicular carcinomas. Poorly differentiated and undifferentiated thyroid carcinomas showed only a partial positivity. NOTCH1 expression pattern also seemed differently distributed according to histotype. Our data confirm a role of NOTCH1 in thyroid cancer and highlight for the first time the specific involvement of this pathway in papillary carcinomas. Our data also indicate that other thyroid malignancies do not rely on NOTCH1 signaling for development and progression.
Collapse
Affiliation(s)
- Simonetta Piana
- Pathology Unit, Azienda USL – IRCCS Reggio Emilia, Reggio Emilia, Italy
| | - Eleonora Zanetti
- Pathology Unit, Azienda USL – IRCCS Reggio Emilia, Reggio Emilia, Italy
| | | | - Alessia Ciarrocchi
- Laboratory of Translational Research, Azienda USL – IRCCS Reggio Emilia, Reggio Emilia, Italy
| | - Davide Giordano
- Otolaryngology Unit, Azienda USL – IRCCS Reggio Emilia, Reggio Emilia, Italy
| | - Federica Torricelli
- Laboratory of Translational Research, Azienda USL – IRCCS Reggio Emilia, Reggio Emilia, Italy
| | - Teresa Rossi
- Laboratory of Translational Research, Azienda USL – IRCCS Reggio Emilia, Reggio Emilia, Italy
| | - Moira Ragazzi
- Pathology Unit, Azienda USL – IRCCS Reggio Emilia, Reggio Emilia, Italy
| |
Collapse
|
2
|
Liu P, Zhang M, Niu Q, Zhang F, Yang Y, Jiang X. Knockdown of long non-coding RNA ANRIL inhibits tumorigenesis in human gastric cancer cells via microRNA-99a-mediated down-regulation of BMI1. ACTA ACUST UNITED AC 2018; 51:e6839. [PMID: 30156609 PMCID: PMC6110352 DOI: 10.1590/1414-431x20186839] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2017] [Accepted: 06/25/2018] [Indexed: 12/19/2022]
Abstract
Long non-coding RNA antisense non-coding RNA in the INK4 locus (ANRIL) has been reported to promote tumorigenesis via regulating microRNA (miR)-99a in gastric cancer cells. However, the role of each component involved in it is still not well understood. This study aimed to verify the role of ANRIL in gastric cancer as well as the underlying mechanisms. ANRIL levels in clinical gastric cancer tissues and cell lines were tested by qPCR. Effects of ANRIL silence on cell viability, migration and invasion, apoptosis, and miR-99a expression in MKN-45 and SGC-7901 cells were measured using CCK-8, Transwell assay, flow cytometry, and qPCR assays, respectively. Then, effects of miR-99a inhibition on ANRIL-silenced cells were evaluated. B-lymphoma Mo-MLV insertion region 1 (BMI1) expression, after abnormal expression of ANRIL and miR-99a, was determined. Finally, expression of key proteins in the apoptotic, Notch, and mTOR pathways was assessed. ANRIL level was elevated in gastric cancer tissues and cell lines. Knockdown of ANRIL suppressed cell viability, migration, and invasion, and increased apoptosis through up-regulating miR-99a. Furthermore, ANRIL silence down-regulated BMI1 via up-regulating miR-99a. BMI1 silence down-regulated Bcl-2 and key kinases in the Notch and mTOR pathways and up-regulated p16 and cleaved caspases. We verified the tumor suppressive effects of ANRIL knockdown in gastric cancer cells via crosstalk with miR-99a. Together, we provided a novel regulatory mechanism for ANRIL in gastric cancer, in which ANRIL silence down-regulated BMI1 via miR-99a, along with activation of the apoptotic pathway and inhibition of the Notch and mTOR pathways.
Collapse
Affiliation(s)
- Pei Liu
- Department of Infectious Diseases, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
| | - Mingming Zhang
- Department of Gastroenterology, Qingdao Municipal Hospital, Qingdao, Shandong, China
| | - Qinghui Niu
- Department of Infectious Diseases, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
| | - Fengjuan Zhang
- Department of Infectious Diseases, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
| | - Yuling Yang
- Department of Infectious Diseases, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
| | - Xiangjun Jiang
- Department of Gastroenterology, Qingdao Municipal Hospital, Qingdao, Shandong, China
| |
Collapse
|
3
|
Li W, Lou J, Wei L, Bai H, Zhang Y, He Y. Ethyl pyruvate protects PC12 cells from oxygen-glucose deprivation: A potential role in ischemic cerebrovascular disease. Biomed Pharmacother 2017; 92:168-174. [DOI: 10.1016/j.biopha.2017.05.067] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2016] [Revised: 04/26/2017] [Accepted: 05/12/2017] [Indexed: 02/02/2023] Open
|
4
|
Zang M, Hu L, Zhang B, Zhu Z, Li J, Zhu Z, Yan M, Liu B. Luteolin suppresses angiogenesis and vasculogenic mimicry formation through inhibiting Notch1-VEGF signaling in gastric cancer. Biochem Biophys Res Commun 2017; 490:913-919. [DOI: 10.1016/j.bbrc.2017.06.140] [Citation(s) in RCA: 47] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2017] [Accepted: 06/22/2017] [Indexed: 02/07/2023]
|
5
|
Hubmann R, Sieghart W, Schnabl S, Araghi M, Hilgarth M, Reiter M, Demirtas D, Valent P, Zielinski C, Jäger U, Shehata M. Gliotoxin Targets Nuclear NOTCH2 in Human Solid Tumor Derived Cell Lines In Vitro and Inhibits Melanoma Growth in Xenograft Mouse Model. Front Pharmacol 2017; 8:319. [PMID: 28736522 PMCID: PMC5500618 DOI: 10.3389/fphar.2017.00319] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2017] [Accepted: 05/15/2017] [Indexed: 12/04/2022] Open
Abstract
Deregulation of NOTCH2 signaling is implicated in a wide variety of human neoplasias. The current concept of targeting NOTCH is based on using gamma secretase inhibitors (GSI) to regulate the release of the active NOTCH intracellular domain. However, the clinical outcome of GSI remains unsatisfactory. Therefore we analyzed human solid tumor derived cell lines for their nuclear NOTCH activity and evaluated the therapeutic potential of the NOTCH2 transactivation inhibitor gliotoxin in comparison to the representative GSI DAPT. Electrophoretic mobility shift assays (EMSA) were used as a surrogate method for the detection of NOTCH/CSL transcription factor complexes. The effect of gliotoxin on cell viability and its clinical relevance was evaluated in vitro and in a melanoma xenograft mouse model. Cell lines derived from melanoma (518A2), hepatocellular carcinoma (SNU398, HCC-3, Hep3B), and pancreas carcinoma (PANC1) express high amounts of nuclear NOTCH2. Gliotoxin efficiently induced apoptosis in these cell lines whereas the GSI DAPT was ineffective. The specificity of gliotoxin was demonstrated in the well differentiated nuclear NOTCH negative cell line Huh7, which was resistant to gliotoxin treatment in vitro. In xenotransplanted 518A2 melanomas, a single day dosing schedule of gliotoxin was well tolerated without any study limiting side effects. Gliotoxin significantly reduced the tumor volume in early (83 mm3 vs. 115 mm3, p = 0.008) as well as in late stage (218 mm3 vs. 576 mm3, p = 0.005) tumor models. In conclusion, NOTCH2 appears to be a key target of gliotoxin in human neoplasias and gliotoxin deserves further evaluation as a potential therapeutic agent in cancer management.
Collapse
Affiliation(s)
- Rainer Hubmann
- Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of ViennaVienna, Austria
| | - Wolfgang Sieghart
- Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of ViennaVienna, Austria
| | - Susanne Schnabl
- Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of ViennaVienna, Austria
| | - Mohammad Araghi
- Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of ViennaVienna, Austria
| | - Martin Hilgarth
- Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of ViennaVienna, Austria
| | - Marlies Reiter
- Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of ViennaVienna, Austria
| | - Dita Demirtas
- Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of ViennaVienna, Austria
| | - Peter Valent
- Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of ViennaVienna, Austria.,Department of Medicine I, Ludwig Boltzmann Cluster Oncology, Medical University of ViennaVienna, Austria
| | - Christoph Zielinski
- Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of ViennaVienna, Austria.,Comprehensive Cancer Center Vienna, Drug and Target Screening Unit, Medical University of ViennaVienna, Austria
| | - Ulrich Jäger
- Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of ViennaVienna, Austria.,Comprehensive Cancer Center Vienna, Drug and Target Screening Unit, Medical University of ViennaVienna, Austria
| | - Medhat Shehata
- Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of ViennaVienna, Austria.,Comprehensive Cancer Center Vienna, Drug and Target Screening Unit, Medical University of ViennaVienna, Austria
| |
Collapse
|